Primer: Bicara Therapeutics (BCAX US) - Aug 2026
Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class bifunctional antibodies for solid...
85 Views
Biopharma Week in Review Large M&A and Licensing Deals Provide a Boost
Gene and cell therapy (NTLA, BEAM, CRSP) got a boost, as the heads of the HHS, FDA, CBER, NIH, and CDC expressed support for faster rare disease...
317 Views
Biopharma Week in Review - FDA Provides Some Certainty for Vaccines; ASCO Abstracts Snippets
Vaccine stocks (NVAX, BNTX, PFE, MRNA, PCVX) had a good week, as the FDA provided new regulatory policy for COVID-19 vaccines.
255 Views
Key Updates on Bicara Therapeutics IPO: ~$800M Valuation at the Midpoint and Strong Balance Sheet
Biocon-backed Bicara Therapeutics will go public this week. With top-tier backers, a promising lead program and strong balance sheet, I expect...
450 Views
Bicara Therapeutics IPO: A Promising Combination with Merck’s Keytruda For Patients With HNSCC
​Bicara Therapeutics, backed by Biocon Limited, files for a $200M IPO in the United States. Their bifunctional antibody in combination with...
437 Views
No more insights